You are here

Exelixix

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

PM Live

Wed, 02/10/21 - 12:09 am

Bristol Myers Squibb

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Yahoo

Sun, 06/5/16 - 11:59 am

clinical trials

advanced renal cell carcinoma

Exelixis Licenses PI3K-Delta Program to Merck

Yahoo

Wed, 12/21/11 - 12:55 pm